Latest Breaking News On - Bio contacts - Page 1 : vimarsana.com

MaxCyte Signs Strategic Platform License with Be Biopharma

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs.

United kingdomAnya bolshemChris welshMaher masoudDavid deuchlerBio bcmsRichard jamesPanmure gordonMary jane elliottEmma earl freddy crossleyRupert deardenDavid rawlingsSeattle children research instituteBristol myers squibbMaxcyte incLongwood fund

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Timothy luSenti biosciences incSecurities exchangeDrug administrationExchange commissionBio announces strategic stepsPrioritize investmentLead clinicalGene circuitLogic gatedInvestigational new drugChief executive officerCelest therapeuticsSpark therapeuticsSenti bioGene circuits

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn., Aug. 7, 2023 /PRNewswire/ PacBio , a leading.

United statesLizelda lopezMike bamshadGustavo stolovitzkyPacific biosciencesTricia truehartGreg corradoMaurissa messierPacbio revioTodd friedmanChristian henryGoogle healthCalifornia incExchange commissionDepartment of pediatricsUniversity of washington school medicine

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care - GeneDx Hldgs (NASDAQ:WGS), Pacific Biosciences (NASDAQ:PACB)

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn., Aug. 7, 2023 /PRNewswire/ PacBio (NASDAQ:PACB), a leading developer of

United statesGreg corradoGustavo stolovitzkyTricia truehartPacific biosciencesTodd friedmanLizelda lopezChristian henryPacbio revioPrnewswire pacbioMaurissa messierMike bamshadExchange commissionUniversity of washingtonSecurities exchangeFred hutchinson cancer center

uniQure Inc : uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

~ License of APB-102 further strengthens uniQure's pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure's c9orf72-ALS

United kingdomNoord hollandDavid rosenJohn reillyChiara russoRicardo dolmetschMariae cantorApic bioTom maloneDrug administrationOrphan drugFast trackQure forward lookingLicense agreementAnnual reportAmyotrophic lateral sclerosis